Weight Loss Injections Shortage: What Patients Need to Know Right Now

Why the shortage happened — and why it keeps resurfacing

When NICE recommended tirzepatide in December 2024 and NHS England began rolling out phased access, the number of people eligible for GLP-1 medicines in the UK grew faster than global production lines could scale. Novo Nordisk and Eli Lilly have both invested heavily in manufacturing capacity, and the NHS England medicines-for-obesity programme notes that supply constraints have shaped how phased NHS access was timed. The result is a market where availability is uneven: a 5mg Mounjaro pen may be readily available while the 10mg is on allocation; Wegovy 1.7mg may be scarce at the same moment 2.4mg is well stocked. It shifts month to month.

The underlying cause is structural. These medicines require complex biological manufacturing, the active molecules are large peptides produced through fermentation processes that cannot simply be switched on at higher volumes overnight. Both manufacturers have been transparent about this, and the MHRA has maintained active dialogue with them throughout. Scarcity is not a sign of anything wrong with the product; it is a consequence of a medicine becoming far more widely prescribed than anyone anticipated within two years of UK licensing.

What official guidance says patients should actually do during a gap

The NHS has been clear that patients should not attempt to bridge a shortage by sourcing medicines outside the licensed UK supply chain. The NHS tirzepatide page and associated prescribing information both state that decisions about pausing, switching or continuing treatment must be made with the prescriber, not independently. Stopping abruptly is not dangerous in the same way as discontinuing some medicines, but without clinical guidance you risk losing progress and restarting at a lower dose than is appropriate for your stage of treatment.

For patients mid-titration, a prescriber may recommend holding at your current dose rather than advancing, switching temporarily to the equivalent available medicine, or pausing and planning a restart. All of these are reasonable clinical choices, which one suits you depends on your individual response so far, your comorbidities, and how long the gap is likely to last. This is exactly the kind of question our clinical team works through with patients regularly. The right answer is never "find it wherever you can."

Counterfeits fill the gap the shortage creates, and they are dangerous

Large seizures of fake weight loss pens have been made by the MHRA, including the first illicit UK manufacturing site producing counterfeit tirzepatide pens, raided in Northampton in October 2025. Approximately 20 million doses with an estimated street value of around £45 million were seized across 2025 enforcement operations alone. Some counterfeit pens seized in earlier operations were found to contain insulin rather than the labelled medicine, a potentially life-threatening substitution. The MHRA Yellow Card scheme allows anyone to report a suspect seller, and this reporting directly feeds enforcement activity.

The shortage amplifies the risk because desperation is the counterfeit market's main recruitment tool. If a legitimate pharmacy tells you a dose is unavailable, a seller offering it immediately at a notable discount is a warning sign, not a solution. Red flags include: sales through social media or unverified websites, offers of these medicines without clinical assessment, and prices well below what the market has settled at since Eli Lilly's list-price increase in September 2025. If you are curious about what private treatment realistically costs through a regulated route, our weight management treatment page sets out what a transparent, all-inclusive price actually covers.

How a GPhC-registered pharmacy reduces your exposure to supply gaps

Not all online pharmacies have equivalent supply-chain access. A pharmacy sourcing through Eli Lilly and Novo Nordisk authorised UK distribution channels is better positioned to anticipate allocation patterns and communicate accurately about availability. At nume, every order is processed through our GPhC-registered pharmacy (registration 9012878), which you can verify directly on the regulator's register. Our prescribers know which doses are available before approving and dispatching an order, there is no point in someone completing a consultation for a pen that we cannot actually send.

If you are exploring weight loss injections for the first time, or you have been mid-treatment with another provider and hit a supply wall, the practical answer is to get a fresh clinical picture before making any changes. A real prescriber, not a queuing system, can review your situation the same day and advise on what is available, what makes clinical sense, and how to plan around supply patterns. That conversation is free. Orders placed before 12pm on weekdays (including the Monday after a long bank-holiday weekend when stock queries tend to pile up) are dispatched the same day once clinically approved, with free next-working-day tracked delivery via DPD.

If you have questions about whether short-term use of weight loss injections makes sense for your situation, or want to understand whether you meet the age and eligibility criteria, our prescribers cover both in the same assessment, alongside any questions you may have about how age requirements apply to weight loss injections. People who are new to this treatment often find it helpful to read about how weight loss shot injections actually work before their consultation, and our weight loss injection overview covers the full range of options available through a regulated UK pharmacy. Start your free consultation and get a clear answer within the day.